If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What information is available about switching to tirzepatide from a GLP-1 receptor agonist?
Eli Lilly and Company has not sponsored any studies on switching to tirzepatide from GLP-1RAs. Health care providers should consider pharmacokinetic/pharmacodynamic profiles of medications and use their best clinical judgment.
See important safety information, including boxed warning, in the attached prescribing information.
Switching From GLP-1 Receptor Agonist
Eli Lilly and Company has not sponsored any studies on the effects of switching between tirzepatide and a glucagon-like peptide-1 receptor agonist.1
Transition Considerations
Physicians should follow their clinical judgment, considering the patient’s glycemic response and needs, when deciding how to transition from a GLP-1 receptor agonist to tirzepatide.1
When transitioning a patient from a GLP-1 receptor agonist to tirzepatide, the prescribing information of tirzepatide and the applicable GLP-1 receptor agonist and pharmacokinetic/pharmacodynamic profiles should be considered including
- dosing and administration
- safety profile
- onset of action
- duration of action
- half-life
- time to steady state, and
- missed dose information.1
Enclosed Prescribing Information
Reference
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: May 19, 2022